Table 1.
Characteristics of the Study Sample
| Characteristic | Placebo | Tamoxifen | P-value |
|---|---|---|---|
| Total Number | 33 | 40 | NA |
| Number dropped | 1 | 3 | NA |
| FOR THOSE COMPLETING BOTH SAMPLINGS | |||
| Age (median and range) | 50.2 (41.6-67.5) | 50.2 (37.0-86.1) | 0.938 |
| Race | |||
| Caucasian, N (%) | 27 (84.4%) | 32 (86.5%) | 1.000 |
| African-American, N (%) |
2 (6.2%) | 2 (5.4%) | |
| Asian, N (%) | 0 (0%) | 1 (2.7%) | |
| Ethnicity | 0.657 | ||
| Hispanic, N (%) | 3 (9.4%) | 2 (5.4%) | |
| Menopausal Status | 0.607 | ||
| Premenopausal | 15 (46.9%) | 14 (37.8%) | |
| Postmenopausal | 17 (53.1%) | 23 (62.2%) | |
| LCIS | 0.696 | ||
| No | 28 (87.5 %) | 34 (91.9%) | |
| Yes | 4 (12.5%) | 3 (8.1%) | |
| > 90% compliant | 30 (93.8%) | 37 (100%) | 0.211 |
| 5-year Gail Risk | 0.436 | ||
| <1.7 | 1 (3.1%) | 2 (5.4%) | |
| 1.7 – 3.3 | 17 (53.1%) | 24 (64.9%) | |
| 3.4 – 4.9 | 12 (37.5%) | 9 (24.3%) | |
| ≥5.0 | 2 (6.3%) | 2 (5.4%) | |
| BMI Kg/M2 (mean) | 29.3 | 27.0 | 0.104 |